No huge bump in share price for Roche after today's news: https://www.bbc.com/news/health-56024772

"Of the patients that received the drug, 596 (29 per cent) died within 28 days. This compared to 394 (33 percent) of patients who died in the control group."

"Data showed that treating patients requiring oxygen and suffering from significant inflammation with tocilizumab and dexamethasone reduced mortality by around one third."

Sure would be nice to see what Apabetalone "far exceeding" the 20% benchmark RVX set looks like.